文献速递痛风与晶体性关节病

URC102(新型hURAT1抑制剂)在健康志愿者中降低血清尿酸

URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该研究为随机双盲安慰剂对照I期试验,在健康男性中评估URC102单次和多次口服的安全性和药效学。URC102在1-10 mg剂量范围内耐受良好,快速降低血清尿酸并维持整个治疗期,剂量依赖性地增加尿酸分数排泄,药代动力学呈剂量比例关系。

要点

  • URC102在健康男性中单次和多次给药1-10 mg耐受良好。
  • URC102快速降低血清尿酸并维持整个治疗期。
  • URC102剂量依赖性地增加尿酸分数排泄,药代动力学呈剂量比例关系。

核心结论

  • URC102在健康男性中安全且有效降低血清尿酸,需在高尿酸血症和/或痛风患者中进一步验证。

主要发现

  • URC102在单次和多次给药后1-10 mg剂量范围内耐受良好。
  • URC102快速降低血清尿酸并维持整个治疗期。
  • URC102剂量依赖性地增加尿酸分数排泄的效应曲线下面积(0-168小时)。
  • URC102的最大血浆浓度和血浆浓度-时间曲线下面积呈剂量比例增加。
  • URC102在韩国人和白种人中的药代动力学和药效学特征相似。

临床怎么用

  • URC102作为hURAT1抑制剂在健康志愿者中显示降尿酸活性,需在痛风患者中进一步研究确认。

局限性

  • 研究仅在健康男性中进行,未纳入高尿酸血症或痛风患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout. We performed a randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic profiles of URC102 after single and multiple oral administration in healthy male subjects. METHODS: Thirty-one Koreans and 23 Caucasians received a single dose of URC102 at 1-30 mg and 1-10 mg, respectively, while 44 Koreans received URC102 once-daily for 7 days at 1-20 mg. We evaluated safety and tolerability throughout the study, and serially determined serum uric acid, the fractional excretion of uric acid and URC102 concentrations. RESULTS: URC102 was well tolerated over the dose range of 1-10 mg after single and multiple administration. URC102 rapidly reduced serum uric acid, which was maintained over the entire treatment period. Furthermore, URC102 increased the area-under-the-effect curve over 168 h for fractional excretion of uric acid in a dose-dependent manner. The maximum plasma concentration and the area under the plasma concentration-time curve of URC102 increased dose-proportionally. The pharmacokinetic and pharmacodynamics characteristics of URC102 were similar in Koreans and Caucasians. CONCLUSION: URC102 was safe and effectively lowered serum uric acid, which should be tested and confirmed in patients with hyperuricaemia and/or gout through further studies. TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01953497 and NCT02524678.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lee HA, Yu KS, Park SI, et al. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Rheumatology (Oxford). 2019. PMID: 31056705. doi:10.1093/rheumatology/kez140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。